Eli Lilly and Company announced a significant expansion at its Pleasant Prairie facility Thursday. The pharmaceutical giant plans a $3 billion investment, which is expected to create 750 new jobs at ...
Prescription fills for weight loss drugs more than doubled in 2024 despite limited insurance coverage and high costs, ...
DealBook Summit, Lilly CEO David Ricks said GLP-1 drugs have the potential to treat more than obesity — including heart disease and substance use disorders.
Ozempic and similar drugs have been linked to possibly helping diseases beyond diabetes and obesity. Are they miracle drugs?
Given the scale of the NHS's problems, from waiting times at record levels to overloaded A&E units, you might have thought it ...
(Reuters) - Eli Lilly said on Thursday it will invest $3 billion to expand the manufacturing plant it bought in Pleasant ...
Eli Lilly & Co. is spending another $3 billion to build out its US manufacturing footprint as it ramps up production of its ...
Data suggests that dramatic weight loss, including via GLP-1 drugs, could save Americans big bucks in healthcare spending.
FILE PHOTO: U.S. Food and Drug Administration (FDA) Commissioner Robert Califf testifies before a Senate Health, Education, ...
Mounjaro has been reserved for those with a body mass index above 35, as well as with an obesity-related illness. Sky's ...
The UK’s advertising watchdog has told ITV News it will tackle “illegal, unacceptable and unfair” adverts for weight-loss ...